Dasatinib-d
Cat. No.：YN270637
| 产品名称: | Dasatinib-d |
| CAS No.: | 1132093-70-9 |
| Chemical Name: | N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl-2,2’,3,3’,5,5’,6,6’-d8]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide |
| Synonyms: | BMS-354825-d |
| 分子量: | 496.1 |
| 分子式: | C22H18ClD8N7O2S |
| SMILES: | OCCN(C([2H])([2H])C1([2H])[2H])C([2H])([2H])C([2H])([2H])N1C2=CC(NC3=NC=C(C(NC4=C(Cl)C=CC=C4C)=O)S3)=NC(C)=N2 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Dasatinib-d8是氘标记的Dasatinib。Dasatinib 是Bcr-Abl和Src家族酪氨酸激酶双抑制剂。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Lombardo, L.J., Lee, F.Y., Chen, P., et al.Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825),a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysJ. Med. Chem.47(27),6658-6661(2004)
Das, J., Chen, P., Norris, D., et al.2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitorJ. Med. Chem.49(23),6819-6823(2006)
Davis, M.I., Hunt, J.P., Herrgard, S., et al.Comprehensive analysis of kinase inhibitor selectivityNat. Biotechnol.29(11),1046-1051(2011)
Carter, T.A., Wodicka, L.M., Shah, N.P., et al.Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesProc. Natl. Acad. Sci. USA102(31),11011-11016(2005)
El-Amm, J., Freeman, A., Patel, N., et al.Bone-targeted therapies in metastatic castration-resistant prostate cancer: Evolving paradigmsProstate Cancer2013,1-10(2013)
Distler, J.H.W., and Distler, O.Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosisRheumatology47(Suppl 5),10-11(2008)
McFarland, K.L., and Wetzstein, G.A.Chronic myeloid leukemia therapy: Focus on second-generation tyrosine kinase inhibitorsCancer Control16(2),132-140(2009)
